Synergy Resources Corporation Announces Pricing of Upsized Public Offering of Common Stock
Synergy Resources Corporation (NYSE MKT: SYRG) ("Synergy" or the "Company") announced today that it has priced an upsized underwritten public offering of 11,500,000 shares of the Company's common stock at $6.25 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock. The Company intends to use the net proceeds from this offering, along with cash on hand, to fund a portion of its 18-month drilling and development budget and additional leasehold acquisition in the Wattenberg Field. Any remaining net proceeds will be used for corporate purposes, including working capital. The offering is expected to settle on June 19, 2013 subject to the satisfaction of customary closing conditions.
GigOptix Secures Position as Leading Independent Component Supplier for 40Gbps/100Gbps High Speed Optical Interconnects Enabling Cloud Applications for Next Generation Data Centers
GigOptix, Inc. (NYSE MKT: GIG), a supplier of advanced semiconductor and optical communications components, reiterates continuous strengthening of its position as the lead independent device supplier for 40Gbps/100Gbps high-speed optical interconnects for emerging Cloud and Web 2.0 applications in next generation data centers.
“With the ever growing demand for our high-speed devices for optical links using pluggables and active optical cables (AOC), and the recent consolidation of some other merchant component manufacturers into vertically integrated system manufacturers, GigOptix is clearly the largest independent supplier of chip-sets to enable high speed optical interconnects in the data centers for short reach (SR) and long reach (LR) high speed connectivity applications.
Gastar Exploration Announces Extension of East Texas Property Sale Closing
Gastar Exploration Ltd. (NYSE MKT: GST) ("Gastar") announced today that the closing of the previously announced sale of Gastar's East Texas properties to Cubic Energy has been extended to June 28, 2013 with a termination date of July 12, 2013 in order to allow Cubic Energy additional time to finalize financing for the transaction. As compensation for the extension of the closing date, the parties have agreed to reduce certain identified due diligence negative adjustments to the purchase price by $350,000.
Midway Receives Another Key Permit for Pan Gold Project, White Pine County, Nevada
Midway Gold Corp. ("Midway" or the "Company") (MDW:TSX-V; MDW:NYSE-MKT) announces receipt of a key permit required for production at its Pan Gold Project in Nevada. The Class I Air Quality Operating Permit to Construct has been issued by the state of Nevada. Additionally, the public comment period for the Pan Draft Environmental Impact Statement (EIS) is closed and the response was overwhelmingly positive. Comments will be incorporated into the Final EIS. The permitting schedule at Pan continues to remain on track for a Fall 2013 Record of Decision by the U.S. Bureau of Land Management.
Vista Gold Corp. Announces Mt. Todd Gold Project Preliminary Feasibility Study And Increase In Reserves Of 44% To 5.9 Million Ounces Of Gold
Vista Gold Corp. ("Vista" or the "Company") (NYSE MKT and TSX: VGZ) today announced the positive results of a new preliminary feasibility study (the "PFS") for its Mt. Todd gold project (the "Project") in Northern Territory, Australia . The PFS evaluates two development scenarios including a 50,000 tonne per day ("tpd") project that develops more of the Mt. Todd resource (the "Base Case") and generates a larger Net Present Value ("NPV") and a smaller and higher-grade 33,000 tpd project that focuses on maximizing return and operating margins (the "Alternate Case"). The PFS was authored by Tetra Tech Inc. with Mine Development Associates, Resource Development Inc., Proteus EPCM Engineers (a Tetra Tech Company), and Power Engineers, Inc.
NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal Health
Virbac Exercises Option to Develop Auriclosene for Use in Global Veterinary Markets
NovaBay Pharmaceuticals, Inc., (NBY), a clinical-stage biotechnology company focused on the topical, anti-infective market, today entered into a collaboration and license agreement with Virbac (NYSE Euronext:VIRP), a global veterinary product company. Virbac exercised its March 2012 Feasibility and Option Agreement, thereby acquiring exclusive worldwide rights to develop NovaBay's proprietary compound, auriclosene (NVC-422), for global veterinary markets. NovaBay will receive an option exercise fee as well as development and pre-commercial milestone payments as a result of the collaboration. NovaBay also expects to receive royalties on the sale of any commercial products in the companion animal field. Virbac's option exercise follows its extensive testing of auriclosene for veterinary uses during the 12-month option period.
Gran Tierra Energy Tests 3,095 Barrels of Oil per Day with Peru Horizontal Well
Initiating Engineering Study to Implement Long Term Test and Bring New Oil to Market
Gran Tierra Energy Inc. ("Gran Tierra Energy") (NYSE MKT: GTE, TSX: GTE), a company focused on oil exploration and production in South America, today provided updates for its exploration drilling in Peru.
"Gran Tierra Energy has successfully completed testing of the sidetrack on the Bretaña Norte 95-2-1XD exploration well in Peru, with results supporting the significant potential production additions expected from the Bretaña field," said Dana Coffield, President and Chief Executive Officer of Gran Tierra Energy.
Overhill Farms Signs Definitive Agreement to Be Acquired by Bellisio Foods
Overhill Farms, Inc. (NYSE MKT: OFI) and Bellisio Foods, Inc. today announced that they have entered into a definitive merger agreement for Bellisio Foods to acquire Overhill Farms in a merger transaction valued at approximately $80.9 million.
Under the terms of the agreement, Overhill Farms shareholders will receive $5.00 in cash for each share of Overhill Farms common stock they own. The transaction represents a 26% premium over the closing price of Overhill Farms common stock on August 13, 2012, prior to the Company's announcement that it was reviewing strategic alternatives, and a 25% premium over the average of the closing price of the common stock during the 60 calendar days ended May 13, 2013, the last day prior to entering into the merger agreement.
Reed's Inc. 1st Quarter 2013 Revenues Increase 24%
Reed's, Inc. (NYSE MKT: REED), maker of the top-selling sodas in natural food stores nationwide, today announced its revenues for its first quarter ended March 31, 2013, and its earnings release date of May 14, 2013.
Revenues for the first quarter of 2013 increased 24% to over $8 million from $6.5 million in the first quarter of 2012. Chris Reed, Founder and CEO, stated, "This is our fourth year of significant growth. Our revenue goals for this first quarter were exceeded and indicate the strength of our continued growth momentum. This is an exciting year unfolding as we continue to expand revenues with our core brands of Reed's Ginger Brews and Virgil's Natural Sodas. Our new Reed's Culture Club Kombucha line of live probiotic cultured teas continues to roll out and gain acceptance. In addition, we continue to develop significant new private label production opportunities. We anticipate continued strong growth for the rest of 2013."
Gran Tierra Energy Inc. Announces Record First Quarter 2013 Results
Major Oil Discovery in Peru; Production, Revenue, Net Income and Funds Flow from Operations Reach New Highs
Gran Tierra Energy Inc. ("Gran Tierra Energy") (NYSE MKT: GTE, TSX: GTE), a company focused on oil and gas exploration and production in South America, today announced its financial and operating results for the quarter ended March 31, 2013. All dollar amounts are in United States ("U.S.") dollars unless otherwise indicated.
Paramount Gold and Silver Extends High Grade Gold and Silver Values Down Dip on Don Ese Vein at San Miguel Project, Mexico
DS-13-032 reports intercepts up to 42.5 g/T gold and 186 g/T silver within a 22.5 meter wide mineralized zone Paramount Gold and Silver Corp. (NYSE MKT:PZG)(PZG.TO)(P6G.F)(WKN:A0HGKQ) ("Paramount") today reported that a new drill program designed to test the depth potential of the high grade Don Ese Vein has intersected outstanding gold and silver grades over greater-than-expected widths, indicating that substantial additional resources could be developed below the current resource model.
OPKO Health To Acquire PROLOR Biotech
—Acquisition Adds Promising Late Stage Product hGH-CTP Targeting Growth Hormone Deficiency and Preclinical Products Targeting Hemophilia, Obesity & Diabetes— —Complementary Drug Development Technologies Strengthen OPKO's Innovation Leadership— —PROLOR to Host Conference Call at 8:30 A.M. EDT Thursday, April 25 to Discuss Transaction—
OPKO Health, Inc. (OPK) and PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins, in an all-stock transaction.
InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
InspireMD, Inc. (NYSE MKT: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ Embolic Protection Stent (EPS), announced today that on April 19, 2013, the Company received an approval with conditions for its Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA). An approval with conditions indicates that the FDA concurs with the overall trial design and while minor details are being finalized, allows the company to initiate enrollment in the MASTER II IDE trial.
The multi-center, randomized trial will consist of 1,114 patients suffering from ST Elevation Myocardial Infarction (STEMI), throughout 35 sites in the U.S. and an additional 35 sites in Europe, and will support the Company's application to market its MGuard™ Prime MicroNet™ covered coronary stent system in the US.
Medgenics Receives Notice of Allowance from the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic Proteins
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the United States Patent and Trademark Office has issued a Notice of Allowance of claims that expand the Company’s scope of patent coverage for additional therapeutic proteins.
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD). NSI-189, the lead compound in Neuralstem's neurogenic small molecule platform, is a proprietary new chemical entity that stimulates new neuron growth in the hippocampus, a region of the brain believed to be implicated in MDD, as well as other diseases and conditions such as: traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis
Trial Expands to Two Centers; Approval Includes Significant Increase in Dosing
Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to commence a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This Phase II dose escalation and safety trial will expand to two centers, Emory University Hospital in Atlanta, Georgia, where Phase I was recently completed, and ALS Clinic at the University of Michigan Health System, in Ann Arbor, Michigan, subject to approval by the Institutional Review Board at each institution. The trial is designed to treat up to 15 patients, in five different dosing cohorts.
American Apparel, Inc. Announces Comparable Sales for March 2013 Increased 8%
American Apparel, Inc. (NYSE MKT: APP), a vertically integrated manufacturer, distributor, and retailer of branded fashion basic apparel, announced preliminary sales for the month ended March 31, 2013, and reported that comparable sales increased 8%, including a 5% increase in comparable store sales for its retail store channel and a 26% increase in net sales for its online channel. Wholesale net sales decreased 7% for the month of March primarily due to one less shipping day in March 2013 than in March 2012. On a preliminary basis, total net sales for March 2013 were $50.3 million, an increase of 2% over the prior year period. For the quarter-ended March 31, 2013, total net sales increased 5% to $138.8 million, with an 8% increase in comparable store sales and a 2% increase in wholesale net sales.
Gastar Exploration Ltd. Declares Monthly Cash Dividend on 8.625% Series A Preferred Stock of Gastar Exploration USA, Inc.
Gastar Exploration Ltd. (NYSE MKT: GST) ("Gastar") announced today that Gastar Exploration USA, Inc., the wholly-owned subsidiary of Gastar, has declared a monthly cash dividend on its 8.625% Series A Preferred Stock ("Series A Preferred Stock") for April 2013.
The dividend on the Series A Preferred Stock is payable on April 30, 2013 to holders of record at the close of business on April 15, 2013. The April 2013 dividend payment will be an annualized 8.625% per share, which is equivalent to $0.179688 per share, based on the $25.00 per share liquidation preference of the Series A Preferred Stock. The Series A Preferred Stock is currently listed on the NYSE MKT and trades under the ticker symbol "GST.PRA."
Navidea Biopharmaceuticals Announces Positive Top-Line Results from Interim Analysis of Lymphoseek® Phase 3 Clinical Trial in Head and Neck Cancer
- Lymphoseek Meets Primary Endpoint in Identification of Sentinel Lymph Nodes Against Pathology Gold Standard -
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced top-line results from the interim analysis of its Phase 3 clinical trial, NEO3-06, of Lymphoseek® (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma.
Gastar Exploration Announces Mid-Continent Acquisition, Resolution of Litigation and Mid-Continent Operational Results
- Will add 157,000 net acres to Gastar's existing Mid-Continent position - Transactions to include repurchase of 6.8 million shares of common stock and settlement of all litigation with Chesapeake
Gastar Exploration Ltd. (NYSE MKT: GST) today announced that it has entered into a definitive agreement to acquire proven reserves and undeveloped leasehold interests in Kingfisher and Canadian counties, Oklahoma from Chesapeake Energy Corporation, repurchase Chesapeake's common shares of the Company and settle all litigation for $85 million. The acquisition includes drilling rights omin approximately 157,000 net acres that adjoin Gastar's existing Mid-Continent acreage and approximately 2.8 MMBoe of proven reserves. The transaction is expected to close on or before June 7, 2013, subject to customary closing adjustments, and with a property purchase effective date of October 1, 2012.